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The objectives of this study were to investigate how diabetes
mellitus (DM) inﬂuences responsiveness of retinal neovessels to
lysophosphatidic acid (LPA) and to elucidate the underlying
mechanism. To this end, we used an ex vivo assay in which
neovessels sprouted from retinal explants (isolated from either
control or DM mice) when cultured between two layers of collagen
and in the presence of vascular endothelial growth factor-A. While
DM had no effect on the formation of neovessels, it prevented LPA-
induced regression. High-glucose (HG) treatment of retinal explants
mimicked the DM phenotype. Similarly, primary retinal endothelial
cells (RECs), which were subjected to HG treatment, organized into
tubes that were resistant to LPA. HG caused LPA resistance within
RECs by elevating ROS, which activated Src-family kinases that
stimulated the extracellular signal–related kinase (Erk) path-
way, which antagonized LPA-mediated signaling events that
were required for regression. This ROS/Src/Erk pathway mecha-
nism appeared to be the same route by which DM induced LPA
resistance of retinal neovessels. We conclude that DM/HG repro-
grams signaling pathways in RECs to induce a state of LPA
resistance. Diabetes 61:1225–1233, 2012
D
iabetic retinopathy is a microvascular (1) com-
plication of diabetes mellitus (DM). With time,
the majority of diabetic patients develop some
degree of diabetic retinopathy, making it one of
the leading causes of preventable blindness in working-age
adults (1,2). Diabetic retinopathy is insidious, slowly altering
the retinal vasculature as it advances through two clinical
stages. The ﬁrst, nonproliferative diabetic retinopathy, pro-
duces microvascular injury, leading to retinal ischemia and
hypoxia. These changes lead to an increase in the vitreal
concentration of proangiogenic factors (3), disrupting angio-
genic homeostasis and facilitating the preretinal proliferation
of blood vessels (angiogenesis) characteristic of the second
stage, proliferative diabetic retinopathy (PDR).
Pan-retinal laser photocoagulation (PRP) is a universally
well-accepted and researched therapy for PDR (1). This
technique consists of applying laser burns over the entire
retina (except the macula), reducing the metabolic demand
and hypoxia of the tissue (1). This arrests the progression
of PDR by reducing the levels of hypoxia-driven angio-
genic factors such as vascular endothelial growth factor
(VEGF) (4). The disadvantage of PRP is the permanent
destruction of portions of retina that results from this ther-
apeutic option.
The realization that the vitreal concentration of VEGF
increases as nonproliferative diabetic retinopathy progresses
to PDR (3) led to the development of anti-VEGF therapy as
an alternative to PRP (1,5). Although most clinical trials
show a substantial beneﬁt, anti-VEGF therapy is not effec-
tive in all patients (6,7). Recent studies found increased
vitreal levels of carbonic anhydrase-I (8) and erythropoietin
(9) in PDR patients. Carbonic anhydrase-I is associated with
macular edema (8), while erythropoietin induces retinal
vascularization in animal models and is more strongly cor-
related with PDR than VEGF (10). These observations sug-
gest that the pathology of PDR involves events and factors in
addition to angiogenesis and VEGF.
Angiogenic homeostasis is the result of the balance be-
tween pro- and antiangiogenic factors (11). Compared with
the proangiogenic side of this balance, the angiomodula-
tors that govern stability/regression have received little
attention (12). Our laboratory has recently demonstrated
that lysophosphatidic acid (LPA) promotes the regression
of unstable vascular beds such as hyaloid vessels in the
developing mouse eye (12). Autotaxin is a secreted enzyme
that generates LPA from lysophosphatidylcholine (13). LPA
is present in the circulation and exerts its effects through six
G-protein–coupled receptors (LPA1–6). LPA1, -3, -4, and -6
are expressed by endothelial cells (14–16). Engagement of
LPA receptors produces a variety of cell responses including
cell migration, proliferation, and survival (13). The action of
LPA on the vascular system appears to be dual; although our
ﬁndings show that LPA promotes the regression of unstable
vascular beds (12), autotaxin/LPA can also induce angio-
genesis (17). It is not obvious which of these functions are
responsible for vascular defects associated with embryonic
lethality in autotaxin-null mice (18). Our working hypothesis
is that the effect of LPA depends on the status of the vas-
culature; LPA promotes angiogenesis of stable vascular beds
by destabilizing them and thereby initiating the angiogenic
program. In an unstable vascular bed, LPA drives regression
by further destabilizing the vessel. The overall goal of this
study was to assess whether DM inﬂuenced the respon-
siveness of retinal neovessels to LPA.
RESEARCH DESIGN AND METHODS
Antibodies and reagents. Anti-mouse and anti-rabbit horseradish peroxidase–
conjugated antibodies and the anti-Src antibody were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). The extracellular signal–related kinase (Erk),
phosphorylated Erk, myosin light chain (MLC)2, phosphorylated MLC2, and
anti–phosphorylated Src antibodies and the mitogen-activated protein kinase
kinase (MEK) inhibitors (PD98059 and U0126) were from Cell Signaling Tech-
nology (Beverly, MA). The pan-LPA receptor antagonist BrP-LPA {1-bromo-3(S)-
hydroxy-4-[(palmitoyloxy)butyl]phosphonate)} was from Echelon Biosciences (Salt
Lake City, UT). LPA (oleoyl-L-a-lysophosphatidic acid sodium salt), D-glucose,
L-glucose, 29,79-dichloroﬂuorescein diacetate (DCFH-DA), N-acetylcysteine (NAC),
and tiron were purchased from Sigma (St. Louis, MO). The Src inhibitors (Su6656
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ORIGINAL ARTICLEand PP2) and streptozotocin were purchased from Calbiochem (Gibbstown, NJ).
The LPA receptor inhibitor Ki16425 was from Cayman Chemical (Ann Arbor, MI).
Diabetes induction in mice. The institutional animal care and use committee
of the Schepens Eye Research Institute approved all animal procedures. Wild-
type C57BL/6J mice ,10 weeks of age were fasted for 4–5 h before being
intraperitoneally injected with streptozotocin (55 mg/kg) dissolved in citrate-
buffered saline solution. The mice received streptozotocin for ﬁve consecutive
days. Three days later, glycemia levels were checked. If glucose levels were
.250 mg/dL, then animals were considered diabetic. Weight loss was con-
trolled with 0.3 units of a 1:10 dilution of subcutaneous NPH insulin (Humulin N;
Lilly, Indianapolis, IN) every other day. The effect of insulin was short, as the day
after administration glucose levels were .250 mg/dL. After 1 month, the mice
were killed and the retinas recovered for explants. Although glucose levels were
not measured at the time of death, previous work (19) shows that in a C57BL/6J
background, DM persists 1 month after streptozotocin injection.
Retinal explants. The explants were isolated and cultured as previously de-
scribed (20). Brieﬂy, retinas were cut into 1-mm
2 pieces and placed in a collagen
sandwich (80% collagen [Advanced Biomatrix], 20 mmol/L HEPES [Lonza,
Walkersville, MD], 0.5 mg/mL ﬁbronectin and laminin [both from Sigma],
2 mg/mL NaHCO3, and 0.02 N NaOH). The collagen sandwich was overlaid with
endothelial basal medium (EBM) (Lonza) supplemented with 10% horse serum
(Lonza), 12 mg/mL bovine brain extract (Hammond Cell Tech, Windsor, CA), and
FIG. 1. Diabetes induced LPA resistance in Rex vessels. Retinas were iso-
lated from age-matched non-DM (A) or streptozotocin-induced DM (B)
mice, cut into approximately 1 mm
2 pieces, and cultured between two layers
of collagen in the presence of VEGF-A (25 ng/mL) for 2–3 weeks. After this
time, LPA (10 mmol/L) was added for 2 days; the medium, containing the
indicated agents, was renewed every 12 h. Vessels treated with buffer per-
sisted (ﬁrst row of A and B). LPA induced regression of vessels derived
from non-DM explants within 2 days (A, second row, white arrows), whereas
the DM ones were unaffected (B, second row). The vessel length before and
after LPA treatment was quantiﬁed, and the results from four independent
experiments are shown in C. Data shown are 6SEM (n= 4). All vessels were
digitally outlined to facilitate their visualization (solid lines). The dashed
outline in (B) indicates an outcropping of the retinal tissue. **P < 0.01. n.s.,
no signiﬁcant difference. Magniﬁcation is 3100 for A and B.
FIG. 2. Hyperglycemia induced LPA resistance in Rex vessels. Retinas
from non-DM mice were cultured as in Fig. 1, except the medium was
modiﬁed to a ﬁnal concentration of 25 mmol/L L-glucose (ﬁrst row of A)
or 25 mmol/L D-glucose (second row of A). The addition of 10 mmol/L LPA
induced regression of L-G Rex on day 2 (white arrows in A)b u tn o to f
HG-Rex vessels. There was no difference between L-G Rex vessels and
those derived from explants cultured in normal glucose conditions
(results not shown). LPA-induced regression was statistically signiﬁcant
in four independent experiments (B). Data shown are 6SEM (n = 4). All
vessels were digitally outlined to facilitate their visualization. *P < 0.05.
n.s., no signiﬁcant difference. Magniﬁcation is 3100.
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observed after 2–3 weeks of treatment. In some experiments, the medium was
altered to achieve a ﬁnal concentration of 25 mmol/L D-o rL-glucose during the
2- to 3-week period of tube formation.
Cellculture.Humanretinalendothelialcells(HRECs)wereacquiredfromCell
Systems (Kirkland,WA).Primary bovineretinal endothelial cells (BRECs) were
isolated as previously described (21). The cells were cultured in endothelial
growth culture medium-2 and EBM (Lonza), respectively. For high glucose
(HG) treatment, endothelial cells were cultured for 10 days in media supple-
mented with additional glucose to a ﬁnal concentration of 25 mmol/L. Control
cells were simultaneously treated with either 25 mmol/L L-glucose or 5 mmol/L
D-glucose. Primary retinal endothelial cells were used between passages
10 and 13. All cells were maintained at 37°C with 5% CO2.
Measurement of intracellular ROS. Control and HG-pretreated BRECs were
cultured as a monolayer in a 96-well plate. Once the cells reached conﬂuence,
they were rinsed twice with Krebs-Ringer solution and incubated in 10 mmol/L
DCFH-DA for 45 min at 37°C. DCFH-DA is readily oxidized by reactive oxygen
species (ROS) into ﬂuorescent dichloroﬂuorescein. Intracellular formation of
ROS was measured at 485/530 nm wavelength on a Synergy 2 plate reader
(Biotek, Winooski, VT). To measure ROS in endothelial cells that had organized
into tubes, the assay was done under low-serum (0.5%) conditions to prevent
spontaneous regression. After tubes formed, they were washed twice with PBS
and incubated for 1 h with 10 mmol/L DCFH-DA. Next, the tubes were washed
two more times with PBS and observed on a Nikon TE-2000S inverted micro-
scope. The pictures were taken with a 1-min exposure to ﬂuorescent light at
3100 magniﬁcation.
Tube assay. The tube assay was performed as previously described (20).
Brieﬂy, BRECs were placed in a collagen gel sandwich and treated with 2.5 ng/mL
VEGF-A. Tube formation was observed 12 h later on a Nikon TE-2000S inverted
microscope. Treatments were performed in fresh media supplemented with
VEGF-A. To observe the effect of endogenous LPA, the assay was performed in
EBM containing 10% horse serum. Low serum diminishes the ability of BRECs to
produce LPA (12). Consequently, the effect of exogenous LPA (1 mmol/L) was
studied in EBM with 0.5% horse serum. Regression was observed 16 h after the
addition of VEGF-A. Normalized tube length is the ratio of ﬁnal and initial tube
length. Pharmacological treatments were added 12 h after the addition of VEGF-
A, when the tubes were ﬁrst observed.
Western blot. Tubes were extracted from the collagen sandwich by dissolving
it with type I collagenase (1 mg/mL; Sigma) for 30 min at 37°C. The liberated
tubes were centrifuged, and the resulting pellets were washed with PBS and
lysed in electrophoresis sample buffer (10 mmol/L EDTA; 4% sodium dodecyl
sulfate; 5.6 mol/L 2-mercaptoethanol; 20% glycerol; 200 mmol/L Tris-HCl, pH
6.8; and 0.2% bromophenol blue). Proteins were resolved on a 10% sodium
dodecyl sulfate–polyacrylamide gel and subjected to Western blot analysis.
Conditioned media was collected from tube assays that contained low serum,
normalized to the total amount of protein present in the sample, and then
subjected to Western blot analysis.
LPA assay. The concentration of LPA in conditioned media samples was mea-
suredusing a radioenzymatic method (22),whichinvolvestheuse ofrecombinant
1-acyl-sn-glycerol-3-phosphate acetyltransferase (23). Brieﬂy, lipids were butanol
extracted and incubated in a reaction mixture containing recombinant LPA
acyltransferase and [
14C]oleoyl-CoA (Perkin-Elmer, Waltham, MA). Subsequently,
the reaction products were resolved by thin-layer chromatography. Under these
conditions, LPA was converted to radioactively labeled phosphatidic acid, which
was identiﬁed by autoradiography and densitometrically quantiﬁed.
Generation of Src overexpressing HRECs. The Src cDNA was obtained
from Open Biosystems and subcloned into the pLXSN vector. The pLXSN-Src
construction was transfected into 293GPG cells. Themediacontaining the virus
was collected for 5 days, concentrated by centrifugation at 25,000g for 90 min,
and used as previously described (20) to infect HREC. Endothelial cells were
selected on the basis of proliferation in the presence of G418 (0.3 mg/mL).
Statistics. Data were analyzed using ANOVA. Differences were considered
statistically signiﬁcant if P , 0.05.
RESULTS
Diabetes induced resistance to LPA in diabetic retinal
explant vessels. The overall goal of this study was to test
whether DM alters the responsiveness of retinal neovessels
FIG. 3. Hyperglycemia induced LPA resistance in tubes. A: Primary BRECs were pretreated for 10 days with NG (5 mmol/L), L-G (25 mmol/L), or
HG (25 mmol/L) and subjected to a tube formation assay in low (0.5%) serum. Tube formation was observed 12 h after the addition of VEGF-A.
Subsequently, tubes received fresh media with or without LPA (1 mmol/L) and were photographed. Four hours later, the same ﬁelds were
rephotographed and evaluated. Tubes treated with buffer did not regress (black arrows). Control tubes treated with LPA regressed (white
arrows). Tubes formed by HG BRECs did not respond to LPA and remained stable (black arrows). B: Four independent experiments were
quantiﬁed. Data shown are 6SEM (n = 4). **P < 0.01. n.s., no signiﬁcant difference. Magniﬁcation is 3100.
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ing eye (12). For this purpose, we focused on vessels that
grew out of retinal explants (Rex) isolated from mice that
endured 1 month of streptozotocin-induced DM or non-
diabetic siblings (non-DM). The vessels were composed of
endothelial cells and appeared to be organized into lumen-
containing structures (Supplementary Fig. 1). Vessel growth
was VEGF-A dependent and equivalent for both groups
(Supplementary Fig. 1D). LPA induced regression of non-
DM Rex vessels, whereas DM-Rex vessels were resistant
(Fig. 1). We conclude that LPA promotes the regression of
nondiabetic retinal vessels and that DM inhibits this re-
sponse. These observations suggest that DM stabilizes ret-
inal neovessels.
HG was sufﬁcient to induce resistance to LPA in Rex
vessels. We investigated whether HG in the ex vivo setting
would recapitulate LPA resistance caused by DM. To this end,
we repeated the experiment shown in Fig. 1 with explants
from non-DM mice, except that the glucose concentration
was either kept at 5 mmol/L or increased to 25 mmol/L
(HG-Rex) (Fig. 2A). As an osmotic control, Rex vessels
w e r ea l s oc u l t u r e di nt h ep r e s e n c eo f2 5m m o l / LL-glucose
(L-G Rex) (Fig. 2A). LPA promoted the regression of L-G
Rex vessels but not of HG-Rex (Fig. 2A and B). The be-
havior of L-G Rex vessels was equivalent to that of non-DM
Rex in a normal concentration (5 mmol/L) of glucose
(results not shown). VEGF-A–dependent vessel formation
was equivalent for all three groups (Supplementary Fig. 1E).
These experiments demonstrate that although DM causes
multiple metabolic changes, HG treatment is sufﬁcient to
model LPA resistance in Rex vessels.
Retinal endothelial cells cultured under hyperglycemic
conditions mimicked the resistance to LPA observed
in diabetic vessels. Our ex vivo experiments did not ad-
dress the cell type(s) that were affected by DM/HG and their
contribution to LPA resistance in DM/HG-Rex vessels.
Consequently, we tested whether retinal endothelial cells
responded to HG and became LPA resistant in the absence of
any other cell types. For this purpose, we used a previously
described tube assay (20,24) in which endothelial cells or-
ganize into tubes in a VEGF-A–dependent manner.
We pretreated BRECs with 25 mmol/L glucose for 10 days
(HG group). As an osmolality control, we simultaneously
pretreated a second group of BRECs with 25 mmol/L
L-glucose (L-G). A third group included cells cultured in
normal conditions (5 mmol/L glucose) (NG). Subsequently,
the cells were subjected to the tube assay. Tube formation
was observed 12 h after VEGF-A addition (Fig. 3A). HG and
L-G treatment did not inﬂuence VEGF-A–dependent tube
formation (results not shown). The overall morphology of
FIG. 4. Hyperglycemia elevated ROS, which was required for LPA resistance. A: Monolayers of control and HG BRECs were incubated for 45 min
with the ROS probe DCFH-DA (10 mmol/L). Emission was read at 528 nm. Analysis of six independent experiments revealed comparable ROS
production in control cells. In contrast, ROS were signiﬁcantly higher in HG-BREC (*P < 0.05). Treatment with the antioxidant NAC reduced ROS
production. B: Tubes organized from the indicated types of BRECs were loaded with DCFH-DA and photographed with an inverted ﬂuorescence
microscope. Fluorescence was barely observed in the control tubes. In contrast, ﬂuorescence was readily apparent in HG tubes. Treatment with NAC
reduced ROS levels below detection in all groups. C: Tubes were formed in serum-containing medium (to permit spontaneous regression) and treated
with the ROS scavenger NAC. Quantiﬁcation of four independent experiments showed that NAC treatment induced regression of HG tubes (**P <
0.01). This regression appeared to be LPA dependent because it was blocked by an LPA receptor inhibitor (BrP-LPA). Data shown are 6SEM.
D: Representative photographs of HG tubes treated with buffer, NAC, or a combination of NAC and BrP-LPA. White and black arrows denote
regressing and stable tubes, respectively. Magniﬁcation is 3100.
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ence in the number of branch points in the three groups
(results not shown). Addition of exogenous LPA (1 mmol/L)
to the tubes after they had formed induced regression in
both control groups, whereas the HG tubes were resistant
(Fig. 3). This result reproduced the events observed in the
ex vivo assay. While a higher dose of LPA (10 mmol/L) also
induced regression of NG tubes, it had no effect on HG
tubes; a lower concentration of LPA (0.1 mmol/L) failed to
promote regression of NG tubes (results not shown). We
conclude that HG is sufﬁcient to induce LPA resistance in
endothelial cells, without the input of the other cell types
present in the retinal explant.
In summary, our ﬁndings show that 1) DM eliminates
the ability of Rex vessels to regress in response to LPA
(enhances their stability), 2)H Gi ss u f ﬁcient to induce LPA
resistance in Rex vessels and primary retinal endothelial
cells, and 3) primary retinal endothelial cells can become
LPA resistant independently of the effect of DM on other
retinal cell types. Therefore, retinal endothelial cells are the
target of HG-mediated LPA resistance.
Hyperglycemia induced resistance to endogenously
produced LPA. The experiments in Figs. 1–3 demonstrate
that DM/HG induces resistance to regression mediated by
exogenous LPA. When the tube assay is performed in 10%
serum, tubes undergo spontaneous regression because of the
combined action of endothelial cell–produced LPA and LPA
from the serum (12,18). Consequently, we tested whether
HG also induced resistance under these spontaneous re-
gression conditions. Supplementary Fig. 2A and B shows
that control tubes formed in the presence of 10% serum
spontaneously regressed, whereas HG tubes remained
stable. The observation that an LPA receptor inhibitor
(10 mmol/L BrP-LPA) prevented tube regression (Supple-
mentary Fig. 2A and B)c o n ﬁrmed that regression of the
control tubes was LPA dependent. We repeated these ex-
periments with primary HRECs and observed similar results
(Supplementary Fig. 3). VEGF-A promoted comparable for-
mation of tubes, which regressed spontaneously in control
conditions but not in the HG setting. Furthermore, LPA re-
ceptor inhibitors BrP-LPA and Ki16425 (10 and 5 mmol/L,
respectively) inhibited regression (Supplementary Fig. 3).
We conclude that exposing either BRECs or HRECs to HG
inhibited spontaneous regression driven by the combination
of endogenously produced and serum-supplied LPA.
Decreased endogenous LPA production was a conceivable
explanation for the resistance to spontaneous regression
observed in HG-treated cells. For instance, HG may inhibit
production and/or secretion of autotaxin, which would re-
duce the amount of LPA and thereby prevent spontaneous
regression. Relative to NG tubes, the amount of autotaxin in
tubes and conditioned medium was reduced, and so was the
quantity of LPA (Supplementary Fig. 2C–H). However, these
parameters were also reduced in L-G tubes, which regressed
as well as NG tubes (Supplementary Fig. 2A and B). Con-
sequently, it did not appear that the small change in the
quantity of autotaxin and LPA was a likely explanation for
HG-induced resistance to spontaneous regression. Further-
more, such a mechanism would be unlikely to explain why
HG tubes failed to regress in response to exogenously added
LPA (Fig. 3). Therefore, we suspected that LPA resistance
arose from interference with LPA-dependent signaling.
FIG. 5. Hyperglycemia increased Src activity, which was required for LPA resistance. A: Representative Western blot of control and HG tube lysates.
Tube lysates were subjected to Western blot analysis using the indicated antibodies. B: The results from four independent experiments were quantiﬁed,
and the results are presented (*P < 0.05). C: Tubes were organized from HG BRECs under conditions that permit spontaneous regression (in the
presence of 10% serum). Regression was observed when Src inhibitors Su6656 (10 mmol/L) or PP2 (10 mmol/L) were included (**P< 0.01). That this
regression was the consequence of LPA action was assessed by inclusion of BrP-LPA (10 mmol/L) with the Src inhibitors. Data shown are 6SEM of four
independent experiments. D: Representative photographs of tubes treated with Su6656 with or without BrP-LPA. White arrows point to regressing
tubes, and black arrows indicate stable tubes. Ⓟ denotes the phosphorylated version of the enzyme. Magniﬁcation is 3100.
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mediated regression. Because oxidative stress produced
by ROS is a common element linking diverse mechanisms
mediating vascular injury in DM (25,26), we investigated the
role of ROS in HG-mediated LPA resistance. Quantiﬁcation
of ROS produced by monolayers of control and HG BRECs
revealed that ROS was elevated in HG BRECs (Fig. 4A).
Similarly, more ROS was visible in tubes organized from HG
BRECs (Fig. 4B). These results suggested that resistance to
regression was related to an elevated level of ROS. Indeed,
the ROS scavenger NAC (27,28) reduced ROS levels (Fig. 4A
and B) and restored spontaneous regression in HG tubes
(Fig. 4C and D). Similar results were obtained with tiron,
another antioxidant (Supplementary Fig. 4). The LPA receptor
inhibitor BrP-LPA prevented regression of NAC-treated tubes,
indicating that regression was LPA dependent. This idea was
reinforced by the observation that NAC failed to promote
regression of tubes in low (0.5%) serum, in which the LPA
level is below the amount necessary for regression (results
not shown). This set of experiments demonstrates that el-
evation of ROS was a key component of HG-induced LPA
resistance.
Src and MEK activity mediated HG-dependent resistance
to LPA. ROS activates Src-family kinases (SFKs) in multiple
cell types, including human pulmonary (29), coronary, and
umbilical vein endothelial cells (30). Our laboratory dem-
onstrated that activation of Src prevents tube regression
(20). To test the impact of HG on Src activity, we assessed
phosphorylation of Src’s Y416 in lysates prepared from
tubes. Phospho-Src was signiﬁcantly higher in HG tubes
(Fig. 5A and B). Furthermore, Src inhibitors (Su6656 and
PP2) promoted tube regression, which was blocked by
coaddition of BrP-LPA (Fig. 5C and D). Moreover, we
observed that a modest overexpression of Src induced LPA
resistance in HRECs (Fig. 6). We conclude that increased Src
activity is a key component of HG-induced LPA resistance.
Since SFK-mediated stability of tubes is dependent on
the Erk pathway (20), we considered their involvement in
HG-mediated resistance to LPA. In tubes organized from
HG BRECs, Erk phosphorylation was elevated and could
be suppressed with NAC (Fig. 7A–D). Furthermore, two dif-
ferent MEK inhibitors rescued LPA-dependent regression
(Fig. 7E and F). These results reveal that HG activates the
Erk pathway and that this event is required for LPA resis-
tance. Finally, since activation of the Erk pathway antago-
nizes RhoA/rho-associated protein kinase (ROCK) (20,31),
which is required for LPA-induced regression (12,20), we
compared phosphorylation of a ROCK substrate, MLC2, in
HG and control tubes. As expected, MLC2 phosphoryla-
tion was reduced in HG tubes (Supplementary Fig. 5).
In summary, our results show that LPA resistance of HG-
treated endothelial cells involves elevated ROS that engages
Src and the Erk pathway and thereby antagonizes essential
LPA-dependent signaling events. These observations sug-
gest that HG reprograms signaling and thereby alters the
response of retinal endothelial cells to angiomodulators
such as LPA.
ROS/Src-mediated desensitization to LPA in diabetic
Rex vessels. Our next step was to test whether the mech-
anism mediating HG-induced LPA resistance described in the
tube assay was relevant to DM-Rex vessels. Indeed, LPA-
mediated regression of DM-Rex vessels was observed in the
presence of either NAC or inhibitors of Src or MEK (Fig. 8A
and B). No regression was observed if the inhibitors were
added alone (Fig. 8B). We propose the following model to
explain how DM/HG blunts the responsiveness of endothelial
cells/vessels to LPA (Fig. 8C). Hyperglycemia elevates the
level of ROS, which activates SFKs that promote the Erk
pathway. The Erk pathway antagonizes RhoA/ROCK, which
is required for LPA-mediated regression (12,20).
DISCUSSION
We found that DM induced resistance to LPA-mediated re-
gression of retinal neovessels. Furthermore, HG mimicked
DM-induced LPA resistance in both ex vivo retinal neo-
vessels and in vitro tubes organized from primary retinal
endothelial cells. Finally, LPA resistance resulted from DM/
HG-induced reprogramming of signaling pathways that were
required for LPA-dependent regression (Fig. 8C).
Our work is not the only example in which DM/HG re-
programs signaling pathways within vascular cells. Geraldes
et al. (32), reported that DM and HG led to persistent acti-
vation of protein kinase C-d in retinal capillaries and peri-
cytes, which precipitated nuclear factor-kB–independent
apoptosis of retinal pericytes (32). Furthermore, reestab-
lishing normoxia by insulin administration did not correct
the elevated protein kinase C-d activity, which indicates that
DM/HG-induced reprogramming of cell signaling is persis-
tent. This phenomenon was also observed in studies pre-
sented herein; neovessels that formed from retinas of DM
mice were LPA resistant, even after 2–3 weeks of culture in
normoglycemic conditions. Thus, LPA resistance appears
to be a manifestation of metabolic memory.
The majority of new PDR therapies have focused on
controlling the angiogenic effects of VEGF. Although the
use of these new drugs induces regression of preretinal
neovascularization in a signiﬁcant number of patients, anti-
VEGF therapy does not beneﬁt all patients. For instance,
FIG. 6. Src overexpression induced LPA resistance in HRECs. HRECs
that had been infected with a retrovirus expressing an empty vector (EV)
or c-Src cDNA (Src-OE) were subjected to a tube assay under conditions
that do not promote spontaneous regression (0.5% serum). A and B:
Western blot analysis of tube lysates revealed an increased level of
both Src and phospho-Src in Src-OE tubes. C and D: Tube response
under the indicated conditions. Overexpressing Src phenocopied HG-
induced LPA resistance (Supplementary Fig. 3). Data shown are 6SEM
of three independent experiments. The black arrows point to stable
tubes. Ⓟ denotes the phosphorylated version of the enzyme. *P < 0.05.
n.s., no signiﬁcant difference.
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37.5% of PDR patients still present retinal neovascu-
larization. Other studies indicate that 75% of diabetic reti-
nopathy patients treated with Bevacizumab continue to
present residual neovascularization (7). Unpublished work
by our laboratory indicates that LPA is present in vitreous
of nondiabetic patients and promotes regression of tubes.
Taken together, these observations suggest that patho-
genesis of PDR results from not only a rise in the level of
proangiogenic agents in vitreous but also a resistance of
retinal neovessels to regression factors such as LPA.
The HG-initiated ROS/Src/Erk pathway mediating LPA re-
sistance (Fig. 8C) provides multiple targets for potential new
therapies for PDR. For instance, antioxidants are an attrac-
tive choice, especially in light of the fact that ROS levels are
elevated in vitreous of diabetic retinopathy patients and in-
crease as the disease progresses to PDR (33). However, di-
etary antioxidant therapies for diabetic retinopathy have led
to ambiguous results (26). Although animal studies were
promising, the results in human studies were contradictory.
For instance, oral antioxidant supplementation decreases
ROS activity in plasma and is associated with delayed di-
abetic retinopathy progression in type 2 diabetes (34). On the
other hand, Millen et al. (35) showed that dietary supple-
mentation with vitamins A and E had no effect on diabetic
retinopathy progression. The reason for these discrepancies
is not clear. Not being able to measure ROS levels and hence
the efﬁciency of treatment on the desired target represents
a major roadblock in the area of research.
The studies presented herein are consistent with the
idea that inhibition of Src activity may promote regression
of retinal neovessels and thereby be a potential therapy for
patients with PDR. Support for this idea includes the ob-
servation that topical administration of Src inhibitors sig-
niﬁcantly reduces vascular leakage induced by intravitreal
injection of VEGF (36). Importantly, there are tyrosine ki-
nase inhibitors with the capacity of targeting Src (37,38) that
are Food and Drug Administration approved for the treat-
ment of leukemia and renal cell carcinoma (dasatinib and
sunitinib, respectively) (37,39). Our ﬁndings beg the ques-
tion of whether these agents would be beneﬁcial for man-
agement of patients with PDR.
FIG. 7. Hyperglycemia-mediated resistance to LPA was dependent on Erk/MEK activity. A: Representative Western blot of Erk phosphorylation
in tube lysates. B: Quantiﬁcation of three independent experiments demonstrated that Erk phosphorylation was signiﬁcantly (*P < 0.05)
increased in HG tubes. C and D: Treatment of HG tubes with NAC signiﬁcantly reduced Erk activity (*P < 0.05). E and F: HG BRECs were
subjected to a tube assay under conditions that were permissive for spontaneous regression (10% serum) in the presence of the indicated
agents: PD98059 (20 mmol/L) and U0126 (10 mmol/L) (**P < 0.05). White arrows point to regressing tubes and black to stable tubes. Ⓟ denotes
the phosphorylated version of the enzyme. Data shown are 6SEM. Magniﬁcation is 3100.
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